FindTrial
Sign In

18F-FES estrogen receptor imaging of breast cancer

18F-FES estrogen receptor imaging of breast cancer

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300069235
Enrollment
Unknown
Registered
2023-03-10
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

experimental group:18F-FES estrogen receptor imaging of breast cancer

Sponsors

West China Hosipital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1. Adult subjects with recurrent or metastatic breast cancer clinically confirmed by West China Hospital, and at least one metastatic lesion in baseline whole body bone imaging (WBS), computed tomography (CT), ultrasound (US) or magnetic resonance imaging (MRI); 2. Have not used estrogen receptor (ER) antagonists (tamoxifen or fluvastatin, etc.) for at least 5 weeks; 3. 18F-FESPECT/CT or PET/MRI imaging can be accepted if conditions 1 and 2 are met.

Exclusion criteria

Exclusion criteria: Pregnant and lactating subjects.

Design outcomes

Primary

MeasureTime frame
standard uptake value;—

Countries

China

Contacts

Public ContactFan Chengzhong

West China Hosipital of Sichuan University

chengzhong.fan@scu.edu.cn+86 189 8060 1858

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026